Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00254657 · ClinicalTrials.gov registry record · NA

Levetiracetam for Treatment of Pain Associated With Fibromyalgia

A NA study, sponsored by University of California, San Francisco.

Completed
Registry status
NA
Development phase
66
Enrollment target

NCT00254657 is a NA study that has completed, run by University of California, San Francisco. The registered enrollment target is 66 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00254657, a NA study, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
NA
Development phase
66 participants
Enrollment target

Study Summary

The purpose of this study is to assess the safety and effectiveness of levetiracetam in reducing the pain of fibromyalgia when compared to placebo. Levetiracetam, an anti-seizure drug, is currently FDA-approved and marketed for use in patients with seizures. Levetiracetam may relieve pain by reducing abnormal activity in the nervous system. A placebo is an inactive substance.

Interventions

  • DRUG Placebo
  • DRUG Levetiracetam

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2004-03
Est. Completion 2005-04
Phase NA

What the Registry Record Tells You About NCT00254657

The ClinicalTrials.gov registry entry for NCT00254657 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00254657 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00254657 about?

NCT00254657 is a clinical study titled "Levetiracetam for Treatment of Pain Associated With Fibromyalgia". The purpose of this study is to assess the safety and effectiveness of levetiracetam in reducing the pain of fibromyalgia when compared to placebo. Levetiracetam, an anti-seizure drug, is currently FDA-approved and marketed for use in patients with seizures. Levetiracetam may relieve pain by reducin...

What is the current status of trial NCT00254657?

This trial is currently completed. It is a NA study. The enrollment target is 66 participants. The study started on 2004-03. Estimated completion is 2005-04.

What interventions are being tested in trial NCT00254657?

The interventions under investigation include: Placebo (DRUG), Levetiracetam (DRUG).

Who is sponsoring clinical trial NCT00254657?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.